Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection.

Kloprogge F, Hammond R, Kipper K, Gillespie SH, Della Pasqua O.

Sci Rep. 2019 Sep 13;9(1):13228. doi: 10.1038/s41598-019-49556-5.

2.

Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

Kloprogge F, Hammond R, Copas A, Gillespie SH, Della Pasqua O.

J Antimicrob Chemother. 2019 Aug 25. pii: dkz369. doi: 10.1093/jac/dkz369. [Epub ahead of print]

PMID:
31504558
3.

Revising Pediatric Vancomycin Dosing Accounting for Nephrotoxicity in a Pharmacokinetic-Pharmacodynamic Model.

Kloprogge F, Hill LF, Booth J, Klein N, Irwin AD, Dixon G, Standing JF.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00067-19. doi: 10.1128/AAC.00067-19. Print 2019 May.

4.

Pharmacokinetic-pharmacodynamic modelling to investigate in vitro synergy between colistin and fusidic acid against MDR Acinetobacter baumannii.

Phee LM, Kloprogge F, Morris R, Barrett J, Wareham DW, Standing JF.

J Antimicrob Chemother. 2019 Apr 1;74(4):961-969. doi: 10.1093/jac/dky524.

5.

Correction to: Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children.

Boonsathorn S, Cheng I, Kloprogge F, Alonso C, Lee C, Doncheva B, Booth J, Chiesa R, Irwin A, Standing JF.

Clin Pharmacokinet. 2019 Jan;58(1):141. doi: 10.1007/s40262-018-0722-x.

6.

Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.

Kloprogge F, Workman L, Borrmann S, Tékété M, Lefèvre G, Hamed K, Piola P, Ursing J, Kofoed PE, Mårtensson A, Ngasala B, Björkman A, Ashton M, Friberg Hietala S, Aweeka F, Parikh S, Mwai L, Davis TME, Karunajeewa H, Salman S, Checchi F, Fogg C, Newton PN, Mayxay M, Deloron P, Faucher JF, Nosten F, Ashley EA, McGready R, van Vugt M, Proux S, Price RN, Karbwang J, Ezzet F, Bakshi R, Stepniewska K, White NJ, Guerin PJ, Barnes KI, Tarning J.

PLoS Med. 2018 Jun 12;15(6):e1002579. doi: 10.1371/journal.pmed.1002579. eCollection 2018 Jun.

7.

Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children.

Boonsathorn S, Cheng I, Kloprogge F, Alonso C, Lee C, Doncheva B, Booth J, Chiesa R, Irwin A, Standing JF.

Clin Pharmacokinet. 2019 Jan;58(1):53-61. doi: 10.1007/s40262-018-0658-1. Erratum in: Clin Pharmacokinet. 2018 Dec 17;:.

8.

Key acceptability attributes of orodispersible films.

Scarpa M, Paudel A, Kloprogge F, Hsiao WK, Bresciani M, Gaisford S, Orlu M.

Eur J Pharm Biopharm. 2018 Apr;125:131-140. doi: 10.1016/j.ejpb.2018.01.003. Epub 2018 Jan 31.

PMID:
29355687
9.

End of the Road for Adjunctive Vitamin D Therapy for Pulmonary Tuberculosis?

Abubakar I, Kloprogge F.

Am J Respir Crit Care Med. 2017 Sep 1;196(5):544-545. doi: 10.1164/rccm.201707-1509ED. No abstract available.

PMID:
28759259
10.

Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border.

Kloprogge F, McGready R, Hanpithakpong W, Blessborn D, Day NP, White NJ, Nosten F, Tarning J.

Antimicrob Agents Chemother. 2015 Oct;59(10):6375-84. doi: 10.1128/AAC.00267-15. Epub 2015 Aug 3.

11.

Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation.

Kloprogge F, McGready R, Phyo AP, Rijken MJ, Hanpithakpon W, Than HH, Hlaing N, Zin NT, Day NP, White NJ, Nosten F, Tarning J.

Br J Clin Pharmacol. 2015 Oct;80(4):642-53. doi: 10.1111/bcp.12660. Epub 2015 Jul 22.

12.

Statistical power calculations for mixed pharmacokinetic study designs using a population approach.

Kloprogge F, Simpson JA, Day NP, White NJ, Tarning J.

AAPS J. 2014 Sep;16(5):1110-8. doi: 10.1208/s12248-014-9641-4. Epub 2014 Jul 11.

13.

Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.

Kloprogge F, Jullien V, Piola P, Dhorda M, Muwanga S, Nosten F, Day NP, White NJ, Guerin PJ, Tarning J.

J Antimicrob Chemother. 2014 Nov;69(11):3033-40. doi: 10.1093/jac/dku228. Epub 2014 Jun 25.

14.

Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda.

Kloprogge F, Piola P, Dhorda M, Muwanga S, Turyakira E, Apinan S, Lindegårdh N, Nosten F, Day NP, White NJ, Guerin PJ, Tarning J.

CPT Pharmacometrics Syst Pharmacol. 2013 Nov 13;2:e83. doi: 10.1038/psp.2013.59.

15.

Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda.

Tarning J, Kloprogge F, Dhorda M, Jullien V, Nosten F, White NJ, Guerin PJ, Piola P.

Antimicrob Agents Chemother. 2013 Oct;57(10):5096-103. doi: 10.1128/AAC.00683-13. Epub 2013 Aug 5.

16.

Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.

Tarning J, Kloprogge F, Piola P, Dhorda M, Muwanga S, Turyakira E, Nuengchamnong N, Nosten F, Day NP, White NJ, Guerin PJ, Lindegardh N.

Malar J. 2012 Aug 22;11:293. doi: 10.1186/1475-2875-11-293.

17.

Dosing rationale for fixed-dose combinations in children: shooting from the hip?

Cella M, Kloprogge F, Danhof M, Della Pasqua O.

Clin Pharmacol Ther. 2012 Apr;91(4):718-25. doi: 10.1038/clpt.2011.297. Epub 2012 Mar 7.

PMID:
22398964

Supplemental Content

Loading ...
Support Center